ANDROGEN INDEPENDENT METASTATIC DISEASE

$0P01FY2002CANIH

University Of Washington, Seattle WA

Investigators

Linked publications & trials

Paper 29759989 Paper 28364014 Paper 28151719 Paper 27897170 Paper 27375016 Paper 27344294 Paper 27167109 Paper 27081082 Paper 26990456 Paper 26928463 Paper 26890304 Paper 26752304 Paper 26667932 Paper 26621741 Paper 26607774 Paper 26489605 Paper 26250344 Paper 26090669 Paper 26071481 Paper 26058078 Paper 26048576 Paper 25952970 Paper 25847934 Paper 25808865 Paper 25481872 Paper 25432832 Paper 25356728 Paper 25301725 Paper 25267620 Paper 25255306 Paper 25198178 Paper 25124870 Paper 25122198 Paper 25091041 Paper 24998678 Paper 24970477 Paper 24942815 Paper 24847652 Paper 24798453 Paper 24657880 Paper 24556717 Paper 24348248 Paper 24323034 Paper 24249383 Paper 24242705 Paper 24162257 Paper 24098661 Paper 24027426 Paper 23995387 Paper 23993097 Paper 23935962 Paper 23740600 Paper 23722902 Paper 23704282 Paper 23612741 Paper 23533230 Paper 23443136 Paper 23420560 Paper 23414343 Paper 23373788 Paper 23352841 Paper 23334979 Paper 23242739 Paper 23239736 Paper 23107099 Paper 23072969 Paper 22936276 Paper 22908226 Paper 22777769 Paper 22710436 Paper 22558251 Paper 22328019 Paper 22290877 Paper 22240788 Paper 22114732 Paper 22112474 Paper 21949389 Paper 21889725 Paper 21796533 Paper 21703419 Paper 21630292 Paper 21355075 Paper 21351253 Paper 21258401 Paper 20726005 Paper 20644256 Paper 20583133 Paper 20562849 Paper 20417685 Paper 20338164 Paper 20332212 Paper 20164920 Paper 20126477 Paper 20021671 Paper 19996218 Paper 19866469 Paper 19795418 Paper 19773449 Paper 19549916 Paper 19275762

Abstract

The goal of this project is to identify genes that are involved in the transition of prostate cancer cells from the androgen-sensitive non- metastatic state to the highly metastatic androgen independent state and determine their function. Second, we will determine how targeting these genes can decrease the development of metastatic prostate cancer. Since there is evidence that during this progression growth (survival) factors may interact to enhance metastatic potential as androgen control is lost, we will also study the interaction of a growth factor system (insulin-like growth factor) with changes in androgen sensitivity. We will address the hypothesis that: Progression to androgen-independent metastatic prostate cancer involves the activation of the androgen receptor (AR) or androgen regulated signaling pathways and genes by the insulin-like growth factor system. To perform these studies we have developed a unique prostate cancer cell system consisting of a tumorigenic but non-metastatic SV40- T immortalized prostate epithelial line, M2205, with both AR(+) and (-) clones and a highly metastatic subline M12 with AR(+) and (-) clones of which the AR(+) clones are no longer metastatic until the AR function is suppressed. We will perform the following specific aims: Aim 1. To identify alterations in gene expression as prostate cancer cells transition from an androgen-sensitive non-metastatic to an androgen-independent metastatic phenotype. Aim 2. To study the role of th IGF-1R and signaling pathways in progression to metastatic disease and the interaction with androgens and to characterize gene expression changes identified in aim 1 with regard to the functional mediation of androgen- independent growth. Aim 3. To identify approaches to the control of androgen-independent metastatic disease. For this purpose we wish to alter the expression of the IGF-1R and AR in the AI metastatic cell lines.

View original record on NIH RePORTER →